What are the key takeaways for Butterfly Network Inc ($BFLY)?

Revenue growth accelerated to 39.5% YoY in Q2 2026, demonstrating strong demand for the portable ultrasound platform. Gross margins reached 71.4% in Q2 2026, a significant improvement that validates the scalability of the software/hardware revenue model. The company maintains a healthy cash position of $124.7 million, though free cash flow remains negative at -$17.2 million for the quarter.

Butterfly Network Inc (BFLY) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Overview Charts AI Summary Financials Valuation

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Butterfly Network, Inc. ($BFLY)

Butterfly Network Inc (BFLY) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $33 million with diluted EPS of $-0.05 and net income of $-13 million. Operating margin was -41.9%, and free cash flow was $-17 million for the period. Management continues to emphasize the transition toward a more software-centric business model, leveraging AI to enhance diagnostic capabilities for clinicians. The company's focus remains on expanding its enterprise footprint, targeting health systems that can benefit from the scalability of the Butterfly iQ platform across diverse clinical environments. Operational commentary highlights the successful deployment of new software updates and the expansion of the user base. The company continues to invest heavily in R&D to maintain its technology lead, with quarterly R&D spend of $10.5 million. Guidance and outlook remain focused on balancing aggressive top-line growth with long-term margin expansion pathways.

Key Takeaways

1.Revenue growth accelerated to 39.5% YoY in Q2 2026, demonstrating strong demand for the portable ultrasound platform.
2.Gross margins reached 71.4% in Q2 2026, a significant improvement that validates the scalability of the software/hardware revenue model.
3.The company maintains a healthy cash position of $124.7 million, though free cash flow remains negative at -$17.2 million for the quarter.
4.The business model is pivoting toward high-margin software/AI subscriptions, which is critical to offsetting the lower-margin, capital-intensive hardware business.
5.Operating margins remain deeply negative (-41.9%), underscoring that the company is still in a high-investment, growth-at-all-costs phase.
6.Market valuation remains aggressive (EV/Sales ~21.7), reflecting investor confidence in the long-term disruptive potential of the ultrasound-on-a-chip technology.

What They Do

Butterfly Network is a digital health company that has developed the world's first portable, handheld, whole-body ultrasound system using its proprietary Ultrasound-on-a-Chip semiconductor technology. This technology replaces the traditional piezoelectric transducers found in legacy ultrasound machines with silicon-based chips, significantly reducing cost, size, and power consumption. Their primary customers include healthcare providers, ranging from large health systems and hospitals to individual clinicians and medical schools. The Butterfly iQ platform serves a broad spectrum of medical specialties, including emergency medicine, internal medicine, primary care, and global health initiatives, effectively democratizing access to diagnostic imaging. What makes the business model unique is the integration of the handheld device with a cloud-based software platform. This system allows for the seamless capture, sharing, and analysis of ultrasound images, supported by an ecosystem of AI-enabled diagnostic tools that assist clinicians in real-time interpretation.

How They Make Money

Butterfly Network recognizes revenue primarily through two channels: the sale of hardware (the ultrasound devices) and subscription-based software services (SaaS). Hardware is generally recognized upon shipment, while software and enterprise management tools are recognized over the life of the subscription term. Growth is driven by both new customer acquisition and the expansion of the 'enterprise fleet' model, where hospitals subscribe to manage large numbers of devices. Recurring software subscriptions are the strategic focus for improving long-term predictability and margins, though hardware sales currently provide the initial entry point for the customer ecosystem. Key drivers for revenue include the adoption rate of handheld point-of-care ultrasound (POCUS), the successful upsell of AI-powered diagnostic software, and the expansion into international markets and new vertical segments like home health.

Competitive Position

The competitive landscape is split between specialized portable ultrasound players (e.g., Clarius, Vave) and large, diversified medical imaging incumbents (e.g., GE HealthCare, Philips, Siemens Healthineers). While incumbents possess significant scale, Butterfly's core differentiation rests on its proprietary silicon-based chip technology, which allows for a single, whole-body probe that is significantly cheaper to manufacture. Butterfly's competitive moat is based on its intellectual property and the speed of its innovation cycle, which allows it to iterate software capabilities faster than legacy providers tethered to cart-based hardware. However, the company faces pricing pressure and potential market share risks if competitors successfully commoditize the handheld market or if healthcare providers prioritize ecosystem integration over raw performance or price. Financial trends suggest that Butterfly is winning share in the portable segment, evidenced by robust double-digit revenue growth. However, its lack of scale relative to global imaging conglomerates remains a significant vulnerability, particularly in enterprise procurement cycles where integrated hospital-wide solutions are preferred.

Business Strategy & Moat

Butterfly’s strategy is a 'land and expand' model enabled by a technology-driven moat. The core moat is its ultrasound-on-a-chip semiconductor IP, which creates a durable cost advantage and barrier to entry that is difficult for legacy providers to replicate without significant disruption to their existing cart-based business lines. Switching costs are built into the enterprise software ecosystem. Once a health system integrates Butterfly’s cloud platform into its PACS (Picture Archiving and Communication System) and clinical workflows, it creates stickiness that increases the lifetime value of the customer and reduces churn. The flywheel effect is intended to be driven by more device users generating more imaging data, which in turn feeds the AI diagnostic models, making the software more valuable to every user. Capital allocation is currently R&D heavy, focusing on refining the hardware and, more importantly, expanding the AI software stack. The long-term durability of the moat depends on maintaining the lead in semiconductor integration while successfully transitioning the revenue base to a high-margin recurring software model.

Industry Outlook

The point-of-care ultrasound (POCUS) market is in a structural growth phase as healthcare shifts from centralized diagnostic imaging towards bedside, real-time diagnostics. Macro drivers include the aging global population and the increasing need for cost-effective, preventative imaging to reduce hospital readmission rates. Near-term headwinds include tighter health system budgets and the potential for regulatory scrutiny regarding diagnostic accuracy of handheld devices compared to high-end cart-based machines. However, the secular trend toward digital health and connected diagnostics provides a strong tailwind that should support long-term industry growth.

Growth Drivers

•Expanding enterprise contracts with large health systems seeking to digitize ultrasound workflows.
•Increasing adoption of AI-enabled diagnostic tools that add value to existing hardware subscriptions.
•Market penetration into primary care and home health verticals which were historically underserved by legacy ultrasound.
•International expansion efforts to bring accessible imaging to emerging markets.
•Continuous hardware iteration, such as new, higher-resolution probes that open up more clinical applications.

Recent Developments

•Reported Q2 2026 revenue of $32.6 million, representing 39.5% growth YoY.
•Gross margins reached 71.4% in Q2 2026, marking a significant operational improvement.
•Continued investment in R&D ($10.5 million in Q2) to enhance the AI diagnostic engine.
•Expansion of enterprise fleet management tools to facilitate hospital-wide device integration.

Catalysts

•Potential partnerships with major Electronic Health Record (EHR) providers to deepen workflow integration.
•Upcoming results from clinical studies validating new AI-driven diagnostic features.
•Release of next-generation hardware probes which could expand the addressable clinical market.
•Quarterly earnings reports demonstrating continued progress toward operating margin inflection.

RPO & Key Performance Indicators

•Revenue grew 39.5% YoY in Q2 2026 to $32.6 million, indicating strong market uptake of the platform.
•Gross margin improved to 71.4%, reflecting a successful shift toward a software-heavy revenue mix.

Strengths

•Proprietary ultrasound-on-a-chip technology provides a distinct cost and portability advantage over legacy imaging.
•Rapid revenue growth (39.5% YoY in Q2) indicates strong market fit and successful customer acquisition.
•Gross margins of 71.4% demonstrate strong underlying profitability of the platform and effective cost discipline.
•The software-centric strategy (SaaS/AI) provides a path to recurring, high-margin revenue and improved customer retention.

AI Benefits & Opportunities

•AI-powered diagnostic assistance provides real-time feedback to clinicians, reducing the expertise gap required for imaging.
•The platform leverages the growing database of ultrasound images to improve AI accuracy, creating a data-driven product flywheel.

Risks & Concerns for Butterfly Network, Inc. ($BFLY)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Butterfly Network, Inc. (BFLY, filings period ending June 30, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Aug 13, 2026.

Peers of Butterfly Network, Inc. (BFLY)

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.